首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials
【24h】

Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials

机译:重组因子VIIa对急性静脉曲张破裂出血效果的影响:基于患者的两项两项对照试验的荟萃分析

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background & Aims Two randomized controlled studies have evaluated the effect of recombinant Factor VIIa (rFVIIa) on variceal bleeding in cirrhosis without showing significant benefit. The aim of the present study was to perform a meta-analysis of the two trials on individual patient data with special focus on high risk patients. Methods The primary outcome measure was the effect of rFVIIa on a composite five day endpoint: failure to control bleeding, 5-day rebleeding or death. Analysis was based on intention to treat. High risk was defined as active bleeding on endoscopy while under vasoactive drug infusion and Child-Pugh score >8. Results 497 patients were eligible for the meta-analysis; 308 (62%) had active variceal bleeding at endoscopy (oozing or spurting) and 283 of these had a Child-Pugh score >8. Analysis on the composite endpoint in all patients with bleeding from oesophageal varices did not show any beneficial treatment effect. However, failure rate for the primary composite end-point was significantly lower in treated patients with active bleeding at endoscopy (17%) compared to placebo (26%, p = 0.049). This difference was highly significant in patients with Child-Pugh score >8 and active bleeding at endoscopy (rFVIIa 16%, placebo 27%; p = 0.023). No significant treatment effect was found at 42 days. Five thromboembolic events occurred in rFVIIa treated patients compared to none in placebo treated patients. Conclusions The current meta-analysis shows a beneficial effect of rFVIIa on the primary composite endpoint of control of acute bleeding, prevention of rebleeding day 1-5 and 5-day mortality in patients with advanced cirrhosis and active bleeding from oesophageal varices at endoscopy. A major drawback of the treatment is a potential increased risk of arterial thrombo-embolic events. This treatment might be considered in patients with lack of control of bleeding after standard treatment.
机译:背景与目的两项随机对照研究评估了重组因子VIIa(rFVIIa)对肝硬化静脉曲张破裂出血的作用,但未显示出明显的获益。本研究的目的是对两项试验进行荟萃分析,以个别患者数据为重点,特别关注高危患者。方法主要结果指标是rFVIIa对5天复合终点的影响:未能控制出血,5天再出血或死亡。分析基于治疗意图。高风险被定义为在接受血管活性药物输注且Child-Pugh评分> 8的情况下在内窥镜下活动性出血。结果对497例患者进行了荟萃分析。 308例(62%)在内窥镜检查时有活动性静脉曲张破裂出血(渗出或喷出),其中283例的Child-Pugh评分> 8。所有食管静脉曲张破裂出血患者的复合终点分析均未显示出任何有益的治疗效果。但是,与安慰剂组(26%,p = 0.049)相比,内镜下活动性出血的接受治疗的患者(17%)的主要复合终点失败率明显更低。在Child-Pugh评分> 8且内窥镜下活动性出血的患者中,这一差异具有显着意义(rFVIIa为16%,安慰剂为27%; p = 0.023)。在第42天未发现明显的治疗效果。与接受安慰剂治疗的患者相比,在接受rFVIIa治疗的患者中发生了五次血栓栓塞事件。结论当前的荟萃分析显示,rFVIIa对控制急性出血,预防晚期肝硬化和内镜下食管静脉曲张活动性出血的1-5天再出血和5天死亡率的主要复合终点具有有益作用。该治疗方法的主要缺点是可能增加动脉血栓栓塞事件的风险。对于标准治疗后无法控制出血的患者,可以考虑采用这种治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号